On Monday, Trevi Therapeutics Inc (NASDAQ: TRVI) was -3.52%% drop from the session before settling in for the closing price of $5.96. A 52-week range for TRVI has been $2.36 – $7.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 27.09% over the past five years. When this article was written, the company’s average yearly earnings per share was at 7.67%. With a float of $69.87 million, this company’s outstanding shares have now reached $99.89 million.
Let’s look at the performance matrix of the company that is accounted for 26 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Trevi Therapeutics Inc (TRVI) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Trevi Therapeutics Inc stocks. The insider ownership of Trevi Therapeutics Inc is 41.36%, while institutional ownership is 43.98%. The most recent insider transaction that took place on Mar 25 ’25, was worth 17,365. In this transaction Chief Scientific Officer of this company sold 2,631 shares at a rate of $6.60, taking the stock ownership to the 221,373 shares. Before that another transaction happened on Mar 21 ’25, when Company’s President & CEO sold 5,263 for $6.58, making the entire transaction worth $34,625. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 7.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.45% during the next five years compared to 27.09% growth over the previous five years of trading.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
You can see what Trevi Therapeutics Inc (TRVI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 15.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Trevi Therapeutics Inc (NASDAQ: TRVI) saw its 5-day average volume 1.78 million, a negative change from its year-to-date volume of 1.88 million. As of the previous 9 days, the stock’s Stochastic %D was 8.81%.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 53.36%, which indicates a significant increase from 21.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.65% in the past 14 days, which was lower than the 79.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.33, while its 200-day Moving Average is $4.55. Nevertheless, the first resistance level for the watch stands at $5.91 in the near term. At $6.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.20. If the price goes on to break the first support level at $5.62, it is likely to go to the next support level at $5.50. Assuming the price breaks the second support level, the third support level stands at $5.33.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
There are 117,293K outstanding shares of the company, which has a market capitalization of 685.08 million. As of now, sales total 0 K while income totals -47,910 K. Its latest quarter income was 0 K while its last quarter net income were -10,340 K.
